Literature DB >> 27168811

Secondary erythromelalgia successfully treated with patient-controlled epidural analgesia and interferon α-2b: A case report and review of the literature.

Xingzhi Li1, Yaomin Li2, Yao Qu1, Laijin Lu3.   

Abstract

Erythromelalgia (EM) is a debilitating neurovascular disease that is refractory to numerous treatment modalities. The present study reported the case of a 72-year-old woman diagnosed with EM secondary to polycythemia vera (PV), who was effectively treated with the use of patient-controlled epidural analgesia (PCEA) and interferon α-2b therapy. The study aimed to provide clinical information on this condition based on the findings of the present case and previously-reported cases. PCEA containing local anesthetics and dexamethasone or fentanyl resulted in nearly complete relief of symptoms. Furthermore, continuous use of interferon α-2b for the treatment of the PV completely relieved the EM symptoms. In conclusion, PCEA and interferon α-2b may be promising treatments for EM secondary to PV.

Entities:  

Keywords:  erythromelalgia; interferon; patient-controlled epidural analgesia; polycythemia vera

Year:  2016        PMID: 27168811      PMCID: PMC4840585          DOI: 10.3892/etm.2016.3088

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  15 in total

1.  Nonspecific capillary proliferation and vasculopathy indicate skin hypoxia in erythromelalgia.

Authors:  Ole Magne Kalgaard; Ole Petter Clausen; Ove Johan Mellbye; Torstein Hovig; Knut Kvernebo
Journal:  Arch Dermatol       Date:  2010-11-15

2.  Histopathologic findings in primary erythromelalgia are nonspecific: special studies show a decrease in small nerve fiber density.

Authors:  Mark D P Davis; Roger H Weenig; Joseph Genebriera; Gwen Wendelschafer-Crabb; William R Kennedy; Paola Sandroni
Journal:  J Am Acad Dermatol       Date:  2006-09       Impact factor: 11.527

Review 3.  Functional vascular diseases: Raynaud's syndrome, acrocyanosis and erythromelalgia.

Authors:  H Heidrich
Journal:  Vasa       Date:  2010-02       Impact factor: 1.961

4.  Successful treatment of erythromelalgia with intrathecal hydromorphone and clonidine.

Authors:  S Macres; S Richeimer
Journal:  Clin J Pain       Date:  2000-12       Impact factor: 3.442

5.  Reduced skin capillary density during attacks of erythromelalgia implies arteriovenous shunting as pathogenetic mechanism.

Authors:  Cato Mørk; Knut Kvernebo; Claes L Asker; E Göran Salerud
Journal:  J Invest Dermatol       Date:  2002-10       Impact factor: 8.551

6.  Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.

Authors:  Bin-Tao Huang; Qing-Chun Zeng; Wei-Hong Zhao; Bing-Sheng Li; Rui-Lin Chen
Journal:  Leuk Res       Date:  2014-07-15       Impact factor: 3.156

7.  Microvascular arteriovenous shunting is a probable pathogenetic mechanism in erythromelalgia.

Authors:  C Mork; C L Asker; E G Salerud; K Kvernebo
Journal:  J Invest Dermatol       Date:  2000-04       Impact factor: 8.551

Review 8.  Erythromelalgia: new theories and new therapies.

Authors:  J S Cohen
Journal:  J Am Acad Dermatol       Date:  2000-11       Impact factor: 11.527

Review 9.  Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.

Authors:  Ayalew Tefferi
Journal:  Am J Hematol       Date:  2012-03       Impact factor: 10.047

10.  Aspirin-responsive painful red, blue, black toe, or finger syndrome in polycythemia vera associated with thrombocythemia.

Authors:  J J Michiels; Z Berneman; W Schroyens; H van Urk
Journal:  Ann Hematol       Date:  2003-02-12       Impact factor: 3.673

View more
  2 in total

Review 1.  Erythromelalgia: a cutaneous manifestation of neuropathy?

Authors:  María Bibiana Leroux
Journal:  An Bras Dermatol       Date:  2018 Jan-Feb       Impact factor: 1.896

2.  Case Report and Literature Review: Interventional Management of Erythromelalgia.

Authors:  Gregory Chinn; Zhonghui Guan
Journal:  Transl Perioper Pain Med       Date:  2019-07-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.